Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 7243968, 14 pages
https://doi.org/10.1155/2017/7243968
Review Article

Long Noncoding RNAs as Biomarkers in Cancer

Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Correspondence should be addressed to Damjan Glavač; is.jl-inu.fm@cavalg.najmad

Received 3 March 2017; Accepted 20 April 2017; Published 29 May 2017

Academic Editor: Wai K. Chu

Copyright © 2017 Luka Bolha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Long noncoding RNAs (lncRNAs) are a relatively well-characterized class of noncoding RNA (ncRNA) molecules, involved in the regulation of various cell processes, including transcription, intracellular trafficking, and chromosome remodeling. Their deregulation has been associated with the development and progression of various cancer types, the fact which makes them suitable as biomarkers for cancer diagnosis and prognosis. In recent years, detection of cancer-associated lncRNAs in body fluids of cancer patients has proven itself as an especially valuable method to effectively diagnose cancer. Cancer diagnosis and prognosis employing circulating lncRNAs are preferential when compared to classical biopsies of tumor tissues, especially due to their noninvasiveness, and have great potential for routine usage in clinical practice. Thus, this review focuses on summarizing the perspectives of lncRNAs as biomarkers in cancer, based on evaluating their expression profiles determined in body fluids of cancer patients.